PTC Therapeutics, Inc.
PTCT
$41.34
-$1.48-3.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 213.17M | 196.79M | 186.70M | 210.12M | 307.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 213.17M | 196.79M | 186.70M | 210.12M | 307.06M |
| Cost of Revenue | 141.05M | 172.26M | 147.70M | 130.87M | 150.47M |
| Gross Profit | 72.12M | 24.53M | 39.01M | 79.25M | 156.59M |
| SG&A Expenses | 84.68M | 73.46M | 69.50M | 73.27M | 76.29M |
| Depreciation & Amortization | 3.31M | 3.04M | 2.87M | 51.53M | 77.17M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 229.04M | 248.75M | 220.06M | 255.67M | 303.94M |
| Operating Income | -15.87M | -51.97M | -33.36M | -45.55M | 3.12M |
| Income Before Tax | -94.70M | -97.99M | -85.73M | -84.70M | -157.05M |
| Income Tax Expenses | -28.81M | 8.66M | 13.45M | 6.88M | -1.26M |
| Earnings from Continuing Operations | -65.89M | -106.65M | -99.18M | -91.58M | -155.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.89M | -106.65M | -99.18M | -91.58M | -155.79M |
| EBIT | -15.87M | -51.97M | -33.36M | -45.55M | 3.12M |
| EBITDA | -9.11M | -45.48M | -26.34M | 9.84M | 83.83M |
| EPS Basic | -0.85 | -1.39 | -1.29 | -1.20 | -2.06 |
| Normalized Basic EPS | 0.36 | -0.82 | -0.61 | -0.70 | -0.19 |
| EPS Diluted | -0.85 | -1.39 | -1.29 | -1.20 | -2.06 |
| Normalized Diluted EPS | 0.36 | -0.82 | -0.61 | -0.70 | -0.19 |
| Average Basic Shares Outstanding | 77.20M | 76.93M | 76.73M | 76.50M | 75.49M |
| Average Diluted Shares Outstanding | 77.20M | 76.93M | 76.73M | 76.50M | 75.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
